Vericel Corp. buy tamam
Start price
21.06.17
/
50%
€2.53
Target price
01.11.18
€17.14
Performance (%)
308.21%
End price
01.11.18
€10.31
Summary
This prediction ended on 01.11.18 with a price of €10.31. The BUY prediction by tamam for Vericel Corp. saw massive gains of 308.21%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Vericel Corp. | -0.905% | -0.905% | 43.137% | -1.351% |
| iShares Core DAX® | -1.226% | 2.804% | 14.933% | 16.561% |
| iShares Nasdaq 100 | -1.845% | 2.732% | 26.075% | 54.743% |
| iShares Nikkei 225® | -1.132% | -2.218% | 5.361% | 4.560% |
| iShares S&P 500 | -0.980% | 1.883% | 22.727% | 45.760% |
Comments by tamam for this prediction
In the thread Vericel Corp. diskutieren
tamam stimmt der fundamentalen Bewertung mit dem Ergebnis 'überbewertet' nicht zu
Vericel is first to get FDA approval for the MACI Cartilage Regeneration procedure for knees. Already they have signed and trained over 350 surgeons and are just gearing up revenues which should be at least $150M for this product alone over next 12 months. They also have another FDA approved product in Epicel, and a 3rd ixCell-DXM that has been fast tracked and recently received RMAT status. Also just partnered with ICT in China for distribution of their products in China and South Korea.
Expect current $4 share price to go to at least $10 to $15. Great earnings report recently out.
(Laufzeit überschritten)